Traws Pharma Current Liabilities

What does Traws Pharma do? Traws Pharma Inc, with ticker TRAW and ISIN US68232V8845, is a US-based pharmaceutical company headquartered in Newtown. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry, and employs 16 full-time staff. Traws Pharma Inc. completed its initial public offering on July 25, 2013. The company's website is https://www.onconova.com/. Traws Pharma Inc. focuses on the development of oncology therapeutics, targeting molecular pathways involved in cancer cell proliferation. The company has two clinical-stage programs: narazaciclib (ON 123300), a multi-targeted kinase inhibitor for solid tumors and hematological malignancies, and rigosertib, which is administered alone or in combination for solid tumor treatment. Narazaciclib targets cyclin-dependent kinases (CDKs), AMPK-related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nanomolar concentrations, alongside other tyrosine kinases. The company also supports investigator-initiated studies exploring rigosertib's potential in cancers driven by mutated K-Ras genes, including a Phase I/IIa study combining rigosertib with a PD-1 inhibitor. Traws Pharma Inc. is a clinical-stage biopharmaceutical company engaged in the identification and development of oncology therapeutics. The company's headquarters are located in Newtown, Pennsylvania. The company's website, https://www.onconova.com/, serves as a primary source of information about its operations and research efforts. Traws Pharma is one of the most popular companies on Eulerpool.